Bench to bedside

Restricted Cytotoxic T-Lymphocyte Responses," Biomedicine 96 Medical Research from Bench to Bedside, Washiagton, D.C., May 3—6, 1996. 

Chatenoud L (2003) CD3-specific antibody-induced active tolerance from bench to bedside. Nat. Rev. Immunol 3 123-132... 

Weinshilboum R, Wang L. Pharmacogenomics bench to bedside. Nat Rev Drug Discov 2004 3 739-48. 

Ratain, M. J. (2006) From bedside to bench to bedside to clinical practice an odyssey with iiinotecan. Clin Cancer Res. 12, 1658-1660. 

Efferth T. (2007) Willmar Schwabe Award 2006 Antiplasmodial and antitumor activity of artemisinin — from bench to bedside. Planta Med 73 299-309. 

Rephaeli, A., Zhuk, R. and Nudelman, A. (2000) Prodrugs of butyric acid from bench to bedside synthetic design, mechanisms of action, and clinical applications. Drug Development Research, 50, 379—391. 

Sikka R, Magauran B, Ulrich A, Shannon M. Bench to bedside pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 2005 12(12) 1227-35. 

A.M. Lambeir, C. Durinx, S. Scharpe, I. De Meester, Dipeptidyl-peptidase IV from bench to bedside An update on structural properties, functions, and clinical aspects of the enzyme DPP IV, Grit. Rev. Clin. Lab. Sci. 40 (2003) 209-294. 

N. J. Robertson and O. Iwata, Bench to bedside strategies for optimizing neuroprotection following perinatal hypoxia-ischaemia in high and low resource settings. Early Hum. Dev., 2007,83,801-811. 

Yamada, T. Grisham, MB. In Inflammatory Bowel Disease From Bench to Bedside Targan, S.R Shanahan, F., Eds. Williams Wilkins Baltimore, MD, 1994 pp 133-150. 

Leibenluft, E. (editor). (1999) Gender in mood and anxiety disorders. In Bench to bedside. Washington, DC, American Psychiatric Press, Inc. 

Kahan BD. 2004. FTY720 From bench to bedside. Transplant Proc. 36 531S-543S. 

Feil R, Kemp-Harper B (2006) cGMP signalling from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep 7 149-53... 

Hauptmann J, Sturzebecher J. Synthetic inhibitors ofthrombin and factor Xa from bench to bedside. Thromb Res I 999 93 203-241. 

Marx SO, Marks AR, Bench to bedside the development of rapamycin and its application to stent restenosis. Circulation 2001 8 852-855. 

Moving any novel therapeutic from bench to bedside requires multiple inter-related steps. The first step is the idea embodied in the basic science. Next, that idea must then be... 

In the past 15 years, an extensive amount of preclinical data has been on the reparative potential of cell transplantation in acute and chronic myocardial injury. Since the first preclinical report of functional repair after the injection of autologous skeletal myoblasts into the injured heart in 1998 (7), a variety of cell types or combinations (Table I) have been proposed for transplantation during different stages of CVD (19). Preclinical data has been promising, and in at least one study, the amount of repair achieved with cell transplantation in HF is additive to current medical treatment (20). With the first cardiac clinical application in 2001 (8), the field rapidly moved from bench to bedside, and at present, we are gaining valuable information about the questions to ask and the early answers from both animal and human studies. To date, 19 clinical trials either in AMI (Table 2) or chronic HF have been published (21) (Table 3), including 13, where BM... 

Active Areas of Research Moving Cell Therapy from Bench to Bedside... 

To bring this field forward, we now have to come together and outline a plan for future studies. The diversity of cell types, application techniques, and disease stages can be a hurdle and an opportunity—only collaboration will allow us to move forward as a field instead of expanding information that cannot be combined or compared. We have the opportunity to create a new era in the treatment of CVD, Doing so would require continued bench to bedside and back to bench evaluations, as we learn from early clinical studies find a consensus on preclinical models and the design of clinical trials to maximize the potential of a 21 st-century approach to repairing the injured heart,... 

Lee SU, Wykrzykowska JJ, Laham RJ. Angiogenesis bench to bedside, have we learned anything Toxicol Pathol 2006 34(1)3-10. 

Translating PGx from bench to bedside (or discovery to marketability) is a multidisciplinary problem, involving private and public sector philosophical, societal, cultural, behavioral, educational, drug development, scientific... 

The consensus arising from these meetings was that the translation of IHC methods from bench to bedside , in the sense of use in routine surgical pathology, has been greatly hindered by two key factors. While decades have passed these issues have not been satisfactorily addressed and have not been ameliorated. 

The utilization of relevant animal species/models that can mimic the human physiology as closely as possible is critical in order to provide an activity and a safety profile for the gene therapy product of interest. This way measurable boundaries can be obtained for an acceptable risk-benefit ratio that will allow for the administration of the gene therapy product into the desired human population (i.e., bench to bedside translation Figure 32.9). There should be a... 

---